Sharma Amit, Armstrong Amy E, Posner Marc P, Kimball Pamela M, Cotterell Adrian H, King Anne L, Fisher Robert A, Godder Kamar
Department of Transplantation Surgery, Virginia Commonwealth University, Richmond, VA 23298, U.S.A.
Ann Transplant. 2012 Dec 31;17(4):133-9. doi: 10.12659/aot.883704.
Graft-versus-host disease (GVHD) is an uncommon cause of morbidity and mortality after solid organ transplantation that is most likely under-diagnosed. We describe our single center experience with three cases of GVHD diagnosed over a period of 15 years in a total of 2,271 solid organ transplant recipients.
We describe three case reports: (1) a 3-week old neonate who developed GVHD 16 months after living-related liver transplant, (2) a 14-year old adolescent who developed GVHD 4 months following an unrelated cadaveric pancreas transplant and; (3) a 27-year old male who developed GVHD 18 days after simultaneous kidney-pancreas transplant from an unrelated donor. GVHD was confirmed through skin biopsies, engraftment profile from bone marrow biopsy and variable number tandem repeat analysis. Treatment strategies included use of corticosteroids and sirolimus monotherapy, corticosteroids and mesenchymal stromal cell therapy and reduction of immunosuppression. We observed that African-American race, sexual and HLA mismatching and cytomegalovirus infection may be high risk factors for development of GVHD following solid organ transplant.
GVHD continues to be a rare but fatal complication following solid organ transplantation that demands a high index of clinical suspicion for diagnosis and management. Future approaches may focus on early recognition of risk factors and improving treatment protocols using a combination of mesenchymal stromal cell transplantation with pharmacotherapy.
移植物抗宿主病(GVHD)是实体器官移植后发病率和死亡率的罕见原因,很可能诊断不足。我们描述了我们单中心在15年期间对2271例实体器官移植受者中诊断出的3例GVHD的经验。
我们描述了3例病例报告:(1)一名3周大的新生儿在活体亲属肝移植后16个月发生GVHD;(2)一名14岁青少年在非亲属尸体胰腺移植后4个月发生GVHD;(3)一名27岁男性在接受非亲属供体的同期肾胰腺移植后18天发生GVHD。通过皮肤活检、骨髓活检的植入情况和可变数目串联重复分析确诊为GVHD。治疗策略包括使用皮质类固醇和西罗莫司单药治疗、皮质类固醇和间充质基质细胞治疗以及减少免疫抑制。我们观察到非裔美国人种族、性别和HLA不匹配以及巨细胞病毒感染可能是实体器官移植后发生GVHD的高风险因素。
GVHD仍然是实体器官移植后一种罕见但致命的并发症,诊断和管理需要高度的临床怀疑。未来的方法可能集中在早期识别风险因素以及使用间充质基质细胞移植与药物治疗相结合来改进治疗方案。